Despite a three-product commercial portfolio, a technology platform that has yielded multiple licensing deals and an agreement with NovaBay to co-promote each other’s ophthalmic therapies, Eyenovia said on 15 November that it is considering all strategic options – including a merger or asset divestment – after deciding to discontinue the Phase III CHAPERONE study of MicroPine, its drug-device combination product being studied in pediatric progressive myopia.
Key Takeaways
- Eyenovia learned its Phase III trial of a drug-device combo product for pediatric myopia is not on track to hit its primary endpoint. The company will end the study and consider strategic options.
The New York-based firm revealed that the study’s independent data review committee, upon reviewing available safety and efficacy data for...